Patents Assigned to Universite Claude Bernard Lyon
-
Publication number: 20250041221Abstract: The invention relates to a nanoparticle comprising at least one cationic lipid, at least one neutral lipid, and at least one pH sensitive lipid which differs from said cationic lipid, which can be used as a vector for the transport and release of nucleic acids within cells.Type: ApplicationFiled: December 2, 2022Publication date: February 6, 2025Applicants: Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, Hospices Civils De Lyon, INSERM (Institut National de la Santé et de la Recherche Médicale), Universita Degli Studi Di VeronaInventors: Giovanna Lollo, Valentina Andretto, David Kryza, Eyad Al Mouazen, Mathieu Repellin, Stéphanie Briancon, Laurent Schaeffer, Jacquier Arnaud, Laurent Coudert
-
Patent number: 12202860Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: GrantFiled: April 3, 2023Date of Patent: January 21, 2025Assignees: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
-
Patent number: 12190746Abstract: A method for assisting a user in reading and in learning to read includes displaying a succession of graphemic entities on a screen. These are displayed with first values for several display parameters so as to enable a user to detect and identify them. The method continues with detecting when the user points to a particular graphemic entity with the first values of the display parameters. The screen then simultaneously displays those graphemic entities that are adjacent to the particular graphemic entity with the first values of the display parameters and the particular graphemic entity with second values for the display parameters. At least one of these second values differs from one of the first values for a given display parameter. This enables the user to identify the particular graphemic entity and causes acoustic rendering of a phonemic entity associated with the particular graphemic entity that the user pointed to.Type: GrantFiled: January 31, 2022Date of Patent: January 7, 2025Assignees: Universite Claude Bernard Lyon 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Angela Sirigu, Alice Gomez, Thomas Perret, Guillaume Lio, Jean-René Duhamel
-
Publication number: 20240409588Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: ApplicationFiled: June 13, 2024Publication date: December 12, 2024Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
-
Publication number: 20240343680Abstract: The present invention relates to a process for preparing aromatic acyl derivatives of formula (I) using methanesulfonic acid. The invention further relates to methods for preparing biological active ingredients. such as paracetamol.Type: ApplicationFiled: October 27, 2022Publication date: October 17, 2024Applicants: Centre National de la Recherche Scientifique, Universite Claude Bernard Lyon 1, Institut National des Sciences Appliquees de LyonInventors: Estelle Metay, Marc Lemaire, Marie-Christine Duclos, Marc Daumas, Olivier Pardigon
-
Publication number: 20240294880Abstract: The invention provides a clonal cell line derived from a liver cancer cell line, preferably derived from a Huh7 hepatocarcinoma cell line, engineered to produce and secrete viral particles containing pregenomic RNA of the hepatitis B virus (HBV), predominantly over DNA of HBV, to calibrate quantitative HBV RNA assays.Type: ApplicationFiled: February 29, 2024Publication date: September 5, 2024Applicants: Universite Claude Bernard Lyon 1, Centre National de la Recherche Scientifique, INSERM (Institut National de la Santé et de la Recherche Médicale), Hospices Civils De Lyon, Centre Leon BerardInventors: Massimo Levrero, Fabien Zoulim, Alexia Paturel
-
Patent number: 12037453Abstract: The present invention relates to a polymer of the aromatic polyether type, containing a biosourced furan diol, to a method for producing said polymer, and to the use of said polymer for producing membranes.Type: GrantFiled: August 20, 2019Date of Patent: July 16, 2024Assignees: Roquette Freres, Universite Claude Bernard Lyon 1, Centre National de la Recherche ScientifiqueInventors: Nicolas Jacquel, Sarah Degras, Régis Mercier, Thierry Delaunay
-
Publication number: 20240228546Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: ApplicationFiled: April 3, 2023Publication date: July 11, 2024Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
-
Publication number: 20240132547Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: ApplicationFiled: April 2, 2023Publication date: April 25, 2024Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
-
Publication number: 20240109940Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.Type: ApplicationFiled: November 22, 2023Publication date: April 4, 2024Applicants: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre National De La Recherche Scientifique (CNRS), Ecole Normale Superieure De Lyon, Universite Claude Bernard Lyon 1Inventors: Théophile OHLMANN, Philippe MANGEOT, Emiliano RICCI
-
Patent number: 11845944Abstract: The disclosure relates to a promoter induced by fungal rust. More specifically, the promoter is induced by the pathogen Phakopsora pachyrhizi, i.e. the Asian Soybean Rust. The disclosure further provides for recombinant genes comprising the promoter and methods of producing a transgenic plant that involves introducing or providing the recombinant gene to plant cells to create transgenic plant cells, and regenerating transgenic plants from the transgenic cells.Type: GrantFiled: May 11, 2018Date of Patent: December 19, 2023Assignees: Centre National De La Recherche Scientifique, Institut National des Sciences Appliquees de Lyon, Universite Claude Bernard Lyon 1, BASF Agricultural Solutions Seed US LLCInventors: Lisa Cabre, Sophie Ducerf, Stephane Peyrard, Catherine Sirven, Bernard Pelissier
-
Publication number: 20230278983Abstract: The present invention relates to indole derivatives of formula (I?) as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.Type: ApplicationFiled: July 6, 2021Publication date: September 7, 2023Applicants: Universite Claude Bernard Lyon 1, Institut National de la Sante et de la Recherche Madicale, Centre National de la Recherche Scientifique, Ecole Normale Superieure de Lyon, Commissariat à l'Energie Atomique et aux Energies AlternativesS, Centre Leon BerardInventors: Alexandre Bancet, Claude Cochet, Odile Filhol-Cochet, Isabelle Krimm, Thierry Lomberget, Marc Le Borgne
-
Patent number: 11693003Abstract: The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.Type: GrantFiled: April 24, 2017Date of Patent: July 4, 2023Assignees: Hospices Civil de Lyon, Universite Claude Bernard Lyon 1, Eurobio ScientificInventors: Pierre Miossec, Ndieme Thiam, Jean-Jacques Pin
-
Publication number: 20230045428Abstract: A system for the treatment of microorganisms includes: a textile web having optical fibers in warp and/or weft woven with binding threads in warp and/or weft, each of the optical fibers having invasive alterations along the fiber and allowing the emission of light propagating in the fiber at these alterations; a light source arranged opposite one or both free ends of the optical fibers. The textile web includes metallic warp and/or weft threads woven with the binding threads, the metallic threads being based on a metal having a negative effect on the growth of microorganisms. The light source generates a light beam having at least one wavelength in the visible or ultraviolet spectrum.Type: ApplicationFiled: December 20, 2020Publication date: February 9, 2023Applicants: Brochier Technologies, Centre National de la Recherche Scientifique, Universite Claude Bernard Lyon 1, Institut National De La Sante Et De La Recherche Medicale, Ecole Normale Superieure De LyonInventors: Chantal GUILLARD, Christophe GILBERT, Cédric BROCHIER, Laure PERUCHON, Lina LAMAA, Davide LORITO
-
Patent number: 11529316Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.Type: GrantFiled: December 6, 2019Date of Patent: December 20, 2022Assignees: Universite Claude Bernard Lyon I, Nano-H, Centre National de la Recherche Scientifique—CNRS, Universite Grenoble Alpes, Universite de BordeauxInventors: Yannick Cremillieux, Andrea Bianchi, Sandrine Dufort, Jean-Luc Coll, Francois Lux, Olivier Tillement
-
Patent number: 11512003Abstract: The invention relates to a method for synthesizing ultrasmall silica nanoparticles, useful in particular for diagnostics and/or therapy. More specifically, a method for synthesizing silica nanoparticles, said method comprising the mixing of at least one silane which is negatively charged at physiological pH with at least one silane which is neutral at physiological pH, and/or at least one silane which is positively charged at physiological pH, wherein: —the molar ratio A of neutral silane(s) to negatively charged silane(s) is defined as follows: 0?A?6, —the molar ratio B of positively charged silane(s) to negatively charged silane(s) is defined as follows: 0?B?5, —the molar ratio C of neutral and positively charged silanes to negatively charged silane(s) is defined as follows: 0<C?8. The invention also relates to the obtained ultrasmall silica nanoparticles.Type: GrantFiled: June 8, 2018Date of Patent: November 29, 2022Assignees: NH THERAGUIX, Universite Claude Bernard Lyon 1, Centre National de La Recherche Gantifote—CNRS—Inventors: François Lux, Olivier Tillement, Fabien Rossetti, Vivek Thakare, Vu Long Tran
-
Publication number: 20220220027Abstract: The invention relates to a method for depositing metal particles on a textile support, which comprises: placing at least one textile sheet (1) made of side-emitting optical fibers (2) in contact with a solution containing at least one ionic precursor of a metal to be deposited, the textile sheet (1) being formed from optical fibers (2) woven in warp and/or weft with binding threads in warp and/or weft, each of the optical fibers (2) having invasive alterations (5) along the fiber and allowing the emission of light propagating in the fiber at these alterations (5), the textile sheet (1) being coated on all or part of the surfaces thereof with a layer of semiconductor particles (4) having photocatalytic properties, the textile sheet (1) and the solution being contained in a space of a reactor (9), the space being free of oxygen; illuminating the textile sheet (1) by at least one light source (7) connected to all or part of the free ends (6) of the optical fibers (2), the light source generating light radiatiType: ApplicationFiled: May 5, 2020Publication date: July 14, 2022Applicants: Brochier Technologies, Centre National de la Recherche Scientifique, Universite Claude Bernard Lyon 1Inventors: Eric PUZENAT, Cédric BROCHIER, Davide LORITO, Lina LAMAA, Laure PERUCHON
-
Patent number: 11286557Abstract: A method of preparing a crystalline thin film having a formula MY2 includes (1) preparing an MYx amorphous film by atomic layer deposition on a surface of a substrate, and (2) annealing the amorphous MYx film at 350° C. or more to provide the crystalline MY2 film. The amorphous MYx film is formed from at least one metal M precursor and at least one element Y precursor, wherein x is 1.5 to 3.1, M is tungsten or molybdenum, and Y is sulfur or selenium. Step (1) includes a) introducing a first metal M precursor or element Y precursor into a deposition chamber, b) purging with inert gas, c) introducing a second metal M precursor when the first precursor is element Y, or element Y precursor when the first precursor is metal M, d) purging with inert gas, e) repeating steps a) to d), and f) obtaining the amorphous MYx film.Type: GrantFiled: February 12, 2019Date of Patent: March 29, 2022Assignees: Commissariat A L'Energie Atomique Et Aux Engergies Alternatives, Centre National De La Recherche Scientifique, Universite Claude Bernard Lyon 1, CPE Lyon Formation Continue et RechercheInventors: Stéphane Cadot, Francois Martin, Elsje Quadrelli, Chloé Thieuleux
-
Patent number: 11180556Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: April 23, 2018Date of Patent: November 23, 2021Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Patent number: 11079391Abstract: The invention relates to an in vitro process for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps: a) measuring the level of an inflammatory marker produced by IL-17-sensitive cells incubated in the presence of a biological sample, b) measuring the level of said inflammatory marker produced by said cells incubated in the presence of a biological sample, in the presence of antibodies which neutralize the biological activity of IL-17, and c) determining the IPDL level, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b).Type: GrantFiled: June 5, 2015Date of Patent: August 3, 2021Assignees: Hospices Civils de Lyon, Universite Claude Bernard Lyon 1Inventors: Pierre Miossec, Ndieme Thiam